xanomeline has been researched along with Alzheimer Disease in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 16 (64.00) | 18.2507 |
| 2000's | 3 (12.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Duan, Y; Jia, K; Li, Z; Wang, D; Zhou, Z | 1 |
| Givalois, L; Kim, SH; Lahmy, V; Malmström, S; Maurice, T; Meunier, J; Naert, G; Vamvakides, A; Villard, V | 1 |
| Lindsley, CW; Melancon, BJ; Panarese, JD; Tarr, JC; Wood, MR | 1 |
| Matera, C; Tata, AM | 1 |
| Cannon, CE; Dancho, M; Koser, A; Kuduk, SD; Puri, V; Renger, JJ; Uslaner, JM; Vardigan, JD; Wittmann, M | 1 |
| Cao, X; Hu, JF; Hu, Y; Lei, X; Mei, B; Niu, Y; Su, J; Wang, D; Xiong, J; Yang, L | 1 |
| Cutler, NR; Hurley, DJ; Seifert, RD; Sramek, JJ | 1 |
| Bonate, PL; DeLong, AF; Kasper, SC | 1 |
| Brown, TJ; Shipley, LA | 1 |
| Carter, G; Hamilton, CL; Kirkwood, JA; Williams, RS | 1 |
| Cutler, NR; Dies, F; Hourani, J; Hurley, DJ; Satterwhite, JH; Sramek, JJ; Wardle, TS | 1 |
| Cutler, NR; Sramek, JJ | 1 |
| Barg, Y; Brandeis, R; Fisher, A; Ginzburg, I; Gurwitz, D; Haring, R; Heldman, E; Karton, Y; Klimowsky, S; Korczyn, AD; Marciano, D; Meshulam, H; Pinkas-Kramarski, R; Pittel, Z; Sadot, E; Treves, TA; Verchovsky, R; Vogel, Z | 1 |
| Palacios, JM | 1 |
| Bodick, N; Goldberger, AL; Lipsitz, LA; Mac Mahon, M; Medina, A | 1 |
| Bodick, NC; Bymaster, FP; Cutler, NR; Gauthier, SG; Hurley, DJ; Levey, AI; Offen, WW; Paul, SM; Potter, WZ; Rasmussen, K; Satlin, A; Shannon, HE; Tollefson, GD | 1 |
| Bodick, N; Offen, WW; Renshaw, PF; Satlin, A | 1 |
| Bodick, NC; Lucas, R; Offen, WW; Paul, SM; Satterwhite, J; Shannon, HE; van Lier, R | 1 |
| Belagaje, R; Bymaster, F; Calligaro, D; DeLapp, N; Fink-Jensen, A; Jeppesen, L; Johnstone, E; Little, S; Mitch, C; Sauerberg, P; Shannon, H; Sheardown, M; Thomsen, C; Ward, J; Whitesitt, C; Wu, S | 1 |
| Crawley, JN; McDonald, MP; Wenk, GL; Willard, LB | 1 |
| Bodick, NC; Cutler, NR; Offen, WW; Sramek, JJ; Veroff, AE | 1 |
| Bymaster, FP; Fink-Jensen, A; Hart, JC; Jeppesen, L; Peters, SC; Rasmussen, K; Sauerberg, P; Shannon, HE; Sheardown, MJ; Swedberg, MD | 1 |
| Cao, Y; Dockery, C; el-Assadi, AA; Huang, XP; Liske, J; Messer, WS; Nagy, PI; O'Brien, J; Peseckis, SM; Rajeswaran, WG; Williams, FE; Wroblewski, ME; Zhang, HJ | 1 |
| Anderton, BH; Dayanandan, R; Forlenza, OV; Lovestone, S; Olesen, OF; Spink, JM | 1 |
3 review(s) available for xanomeline and Alzheimer Disease
| Article | Year |
|---|---|
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Topics: Allosteric Regulation; Alzheimer Disease; Animals; Brain; Cognition; Drug Design; Humans; Molecular Targeted Therapy; Muscarinic Agonists; Pyridines; Receptor, Muscarinic M1; Schizophrenia; Thiadiazoles | 2013 |
Pharmacological approaches to targeting muscarinic acetylcholine receptors.
Topics: Alzheimer Disease; Animals; Humans; Muscarinic Agonists; Pyridines; Quinuclidines; Receptors, Muscarinic; Sjogren's Syndrome; Thiadiazoles; Thiophenes | 2014 |
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; GTP-Binding Proteins; Humans; Ligands; Muscarinic Agonists; Nerve Growth Factors; PC12 Cells; Phosphorylation; Pyridines; Quinuclidines; Rats; Receptors, Cholinergic; Signal Transduction; tau Proteins; Thiadiazoles; Thiophenes | 1996 |
9 trial(s) available for xanomeline and Alzheimer Disease
| Article | Year |
|---|---|
The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amylases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoenzymes; Male; Middle Aged; Muscarinic Agonists; Psychotropic Drugs; Pyridines; Receptors, Muscarinic; Saliva; Thiadiazoles | 1995 |
High-performance liquid chromatographic assay for xanomeline, a specific M-1 agonist, and its metabolite in human plasma.
Topics: Alzheimer Disease; Biotransformation; Chromatography, High Pressure Liquid; Humans; Muscarinic Agonists; Pyridines; Reproducibility of Results; Spectrophotometry, Ultraviolet; Thiadiazoles | 1995 |
The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Pyridines; Receptors, Muscarinic; Thiadiazoles | 1995 |
M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.
Topics: Alzheimer Disease; Animals; Clinical Trials as Topic; GTP-Binding Proteins; Humans; Ligands; Muscarinic Agonists; Nerve Growth Factors; PC12 Cells; Phosphorylation; Pyridines; Quinuclidines; Rats; Receptors, Cholinergic; Signal Transduction; tau Proteins; Thiadiazoles; Thiophenes | 1996 |
Effects of central muscarinic-1 receptor stimulation on blood pressure regulation.
Topics: Aged; Alzheimer Disease; Blood Pressure; Female; Heart Rate; Humans; Hypotension, Orthostatic; Male; Muscarinic Agonists; Norepinephrine; Pyridines; Receptors, Muscarinic; Thiadiazoles | 1997 |
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Topics: Alzheimer Disease; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Muscarinic Agonists; Placebos; Pyridines; Thiadiazoles | 1997 |
Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist.
Topics: Acetylcholine; Alzheimer Disease; Brain; Choline; Creatine; Dose-Response Relationship, Drug; Drug Administration Schedule; Frontal Lobe; Glycerylphosphorylcholine; Humans; Magnetic Resonance Spectroscopy; Muscarinic Antagonists; Neurons; Parasympathetic Nervous System; Protons; Pyridines; Thiadiazoles | 1997 |
The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscarinic Agonists; Neurobehavioral Manifestations; Neuropsychological Tests; Psychometrics; Psychotropic Drugs; Pyridines; Thiadiazoles; Treatment Outcome | 1997 |
Efficacy of xanomeline in Alzheimer disease: cognitive improvement measured using the Computerized Neuropsychological Test Battery (CNTB).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Diagnosis, Computer-Assisted; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mental Recall; Middle Aged; Muscarinic Agonists; Neuropsychological Tests; Psychotropic Drugs; Pyridines; Reaction Time; Thiadiazoles; Treatment Outcome | 1998 |
14 other study(ies) available for xanomeline and Alzheimer Disease
| Article | Year |
|---|---|
Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line; Cerebral Cortex; Disease Models, Animal; Exploratory Behavior; Female; Gene Expression; Hippocampus; Male; Maze Learning; Mice; Mice, Transgenic; Neurons; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Pyridines; Thiadiazoles | 2017 |
Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Dose-Response Relationship, Drug; Furans; Glycogen Synthase Kinase 3; Hippocampus; Infusions, Intraventricular; Male; Memory Disorders; Mice; Morpholines; Muscarinic Agonists; Neuroprotective Agents; Oxadiazoles; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, sigma; Signal Transduction; tau Proteins; Thiadiazoles | 2013 |
Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
Topics: Aged; Alzheimer Disease; Animals; Appetitive Behavior; Attention; Cognition; Defecation; Donepezil; Female; Humans; Indans; Macaca mulatta; Male; Muscarinic Agonists; Neuropsychological Tests; Orientation; Piperidines; Problem Solving; Pyridines; Quinolizines; Receptor, Muscarinic M1; Salivation; Thiadiazoles | 2015 |
Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
Topics: Alzheimer Disease; Animals; Brain; Disease Models, Animal; Glial Fibrillary Acidic Protein; Mice; Mice, Knockout; Muscarinic Agonists; Nerve Tissue Proteins; Phosphorylation; Presenilin-1; Presenilin-2; Pyridines; tau Proteins; Thiadiazoles | 2011 |
Determination of xanomeline (LY246708 tartrate), an investigational agent for the treatment of Alzheimer's disease, in rat and monkey plasma by capillary gas chromatography with nitrogen-phosphorus detection.
Topics: Alzheimer Disease; Animals; Capillary Action; Chromatography, Gas; Dogs; Haplorhini; Hexanes; Humans; Hydrogen-Ion Concentration; Microsomes, Liver; Nitrogen; Parasympathomimetics; Phosphorus; Pyridines; Rats; Sensitivity and Specificity; Thiadiazoles | 1995 |
Sensitive liquid chromatographic method for the determination of a specific M1 agonist, LY246708, an investigational agent with potential for the treatment of Alzheimer's disease, in human plasma.
Topics: Alzheimer Disease; Chromatography, High Pressure Liquid; Drugs, Investigational; Freezing; Humans; Indicators and Reagents; Psychotropic Drugs; Pyridines; Specimen Handling; Spectrophotometry, Ultraviolet; Thiadiazoles | 1993 |
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dihydropyridines; Ethics, Medical; Humans; Nootropic Agents; Oximes; Physostigmine; Psychotropic Drugs; Pyridines; Tacrine; Thiadiazoles | 1995 |
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Drug Costs; Drugs, Investigational; Humans; Olanzapine; Pirenzepine; Placebos; Pyridines; Randomized Controlled Trials as Topic; Schizophrenia; Thiadiazoles | 1996 |
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indans; Muscarinic Agonists; Oximes; Phenylcarbamates; Piperidines; Pyridines; Rivastigmine; Tacrine; Thiadiazoles | 1996 |
Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Carbachol; CHO Cells; Cloning, Molecular; Cricetinae; Humans; Muscarinic Agonists; Mutation; Peptide Fragments; Protein Processing, Post-Translational; Pyridines; Receptor, Muscarinic M1; Receptors, Muscarinic; Sweden; Thiadiazoles; Transfection | 1998 |
Coadministration of galanin antagonist M40 with a muscarinic M1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions.
Topics: Acetylcholine; Alzheimer Disease; Animals; Antibodies, Monoclonal; Behavior, Animal; Choice Behavior; Cholinergic Agents; Cholinergic Fibers; Cognition; Disease Models, Animal; Dose-Response Relationship, Drug; Galanin; Immunotoxins; Male; Memory; Muscarinic Agonists; N-Glycosyl Hydrolases; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptors, Muscarinic; Ribosome Inactivating Proteins, Type 1; Saporins; Thiadiazoles | 1998 |
Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Brain; Cholinergic Agonists; Conditioning, Psychological; Disease Models, Animal; Dopamine; Electrophysiology; Male; Mice; Mice, Inbred Strains; Muscarinic Agonists; Neurons; Psychotic Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Cholinergic; Schizophrenia; Thiadiazoles | 2000 |
Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Topics: Alzheimer Disease; Animals; Drug Design; Injections, Intraperitoneal; Ligands; Male; Models, Molecular; Muscarinic Agonists; Mutagenesis, Site-Directed; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Muscarinic M1; Receptors, Muscarinic; Thiadiazoles | 2000 |
Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons.
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Binding Sites; Calcium-Calmodulin-Dependent Protein Kinases; Carbachol; Cells, Cultured; Fetus; Glycogen Synthase Kinase 3; Glycogen Synthase Kinases; Lithium Chloride; Microtubules; Muscarinic Agonists; Neurons; Phosphorylation; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; tau Proteins; Tetrazoles; Thiadiazoles | 2000 |